About this episode
Drugs like Ozempic show potential to help those with addiction with little downside risk. How quickly can their availability be expanded? Nicholas Reville of CASPR makes his case.
Hosted on Acast. See acast.com/privacy for more information.
Get every episode summarized
Each time Cato Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
